The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The cortisol regenerating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) amplifies tissue glucocorticoid levels, particularly in the liver and adipose tissue. The importance of this enzyme in causing metabolic disease was highlighted by transgenic mice which over- or under-expressed 11β-HSD1; consequently, selective 11β-HSD1 inhibitors have been widely developed as novel agents to treat obesity and type 2 diabetes mellitus (T2DM). This review focuses on the importance of 11β-HSD1 in humans which has been more difficult to ascertain. The recent development of a deuterated cortisol tracer has allowed us to quantify in vivo cortisol production by 11β-HSD1. These results have been surprising, as cortisol production rates by 11β-HSD1 are at least equivalent to that of the adrenal glands. The vast majority of this production is by the liver (>90%) with a smaller contribution from subcutaneous adipose tissue and possibly skeletal muscle, but with no detectable production from visceral adipose tissue. This tracer has also allowed us to quantify the tissue-specific regulation of 11β-HSD1 observed in obesity and obesity-associated T2DM, determine the likely basis for this dysregulation, and identify obese patients with T2DM as the group most likely to benefit from selective inhibition of 11β-HSD1. Some of these inhibitors have now reached Phase II clinical development, demonstrating efficacy in the treatment of T2DM. We review these results and discuss whether selective 11β-HSD1 inhibitors are likely to be an important new therapy for metabolic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 2×
“Mice which selectively overexpress 11βHSD1 in adipose tissue develop central obesity, insulin resistance, dyslipidaemia, and hypertension despite having low or normal circulating corticosterone concentrations [10, 11], showing that increased glucocorticoid action in adipose tissue can cause all the features of the met…”
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753
Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 1×
“Interestingly, this is greater than cortisol production by the adrenal glands in the morning (30–35 nmol/min) [22], highlighting the importance of 11βHSD1.”
Masuzaki, H., Yamamoto, H., Kenyon, C. J., Elmquist, J. K., Morton, N. M., Paterson, J. M., Shinyama, H., Sharp, M. G. F., Fleming, S., Mullins, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17845 · Cited by 434 · cited 1×
“Mice which selectively overexpress 11βHSD1 in adipose tissue develop central obesity, insulin resistance, dyslipidaemia, and hypertension despite having low or normal circulating corticosterone concentrations [10, 11], showing that increased glucocorticoid action in adipose tissue can cause all the features of the met…”
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Lindsay, R. S., Wake, D. J., Nair, S., Bunt, J., Livingstone, D. E. W., Permana, P. A., Tataranni, P. A., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030017 · Cited by 225 · cited 1×
“In some of these studies, mRNA levels correlated with markers of the metabolic syndrome such as insulin resistance [43, 44].”
Self-citationLavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207 · cited 1×
“H6PDH generates the NADPH required for 11β-reductase activity, and H6PDH knockout mice have no 11β-reductase activity [33].”
Purnell, J. Q., Kahn, S. E., Samuels, M. H., Brandon, D., Loriaux, D. L., & Brunzell, J. D. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90769.2008 · Cited by 112
Lavery, G. G., Walker, E. A., Tiganescu, A., Ride, J. P., Shackleton, C. H. L., Tomlinson, J. W., Connell, J. M. C., Ray, D. W., Biason-Lauber, A., Malunowicz, E. M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0743 · Cited by 95 · cited 1×
“Supporting this, humans with severe inactivating mutations in H6PDH have low cortisol:cortisone ratios [34].”
Introduction: Changing view of sulfation and the cytosolic sulfotransferases
Falany, C. N. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.1.9034159 · Cited by 80
Cited by
Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073
Pediatric obesity—Long‐term consequences and effect of weight loss
Marcus, C., Danielsson, P., & Hagman, E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13547 · Cited by 267
Mészáros, K., Karvaly, G., Márta, Z., Magda, B., Tőke, J., Szücs, N., Tóth, M., Rácz, K., & Patócs, A. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0743-6 · Cited by 27
Metadata
- Authors
- Stimson, R. H., & Walker, B. R.
- Venue
- hmbci
- Publisher
- Walter de Gruyter GmbH
- Published
- 2013-06-11
- Volume
- 15
- Issue
- 2
- Pages
- 37-48
- ISSN
- 1868-1883 (ISSN-L)
- 1868-1891
- OpenAlex
- W2007386918
- Cited by
- 38
- References
- 12
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. https://app.cochat.ai/papers/10.1515/hmbci-2013-0015
- The paper
- Stimson, R. H., & Walker, B. R. (2013). The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. hmbci. https://doi.org/10.1515/hmbci-2013-0015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.